Pathstone Family Office, LLC Allogene Therapeutics, Inc. Transaction History

Pathstone Family Office, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$32.38 - $44.96 $7,479 - $10,385	-231 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $4,248 - $12,483	231 New	231 $10,000
Q3 2019 Nov 13, 2019	SELL	$26.11 - $32.99 $711,497 - $898,977	-27,250 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$25.56 - $31.09 $696,510 - $847,202	27,250 New	27,250 $732,000
Q1 2019 May 14, 2019	SELL	$24.82 - $32.54 $657,730 - $862,310	-26,500 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$22.5 - $33.3 $596,250 - $882,449	26,500 New	26,500 $713,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $298M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

Stay updated on Pathstone Family Office, LLC with notifications on news.